--- title: Diagnostic Precision Blog | NTRK description: NTRK | A SeraCare blog focused on precision medicine and advanced clinical diagnostics --- [![SeraCare](https://blog.seracare.com/hs-fs/hubfs/0.%20Logos/SeraCare/SeraCare.png?width=400&name=SeraCare.png "SeraCare")](https://www.seracare.com) - [Home](https://blog.seracare.com/ngs) - [About](https://digital.seracare.com/about-blog) - [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx) - [Contact](http://www.seracare.com/Contact/tabid/366/Default.aspx) ## [Diagnostic Precision](https://blog.seracare.com/) A SeraCare blog focused on precision medicine and advanced clinical diagnostics Choose your Article Focus | [NGS](https://blog.seracare.com/ngs) | [Molecular & Serology](https://blog.seracare.com/molecular-serology-blog) ## [Diagnostic Testing Schemes for NTRK Cancers: All Roads Lead to NGS](https://blog.seracare.com/ngs/diagnostic-testing-schemes-for-ntrk-cancers-all-roads-lead-to-ngs) Category: [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [NTRK](https://blog.seracare.com/ngs/tag/ntrk), [NGS](https://blog.seracare.com/ngs/tag/ngs), [RNA fusion](https://blog.seracare.com/ngs/tag/rna-fusion) Posted by [Russell Garlick, PhD](https://blog.seracare.com/ngs/author/russell-garlick-phd) on Feb 12, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/iStock_000046561376_XXXLarge.jpg)](https://blog.seracare.com/ngs/diagnostic-testing-schemes-for-ntrk-cancers-all-roads-lead-to-ngs) New treatment options for cancer patients with neurotrophic tyrosine kinase (NTRK) rearrangements are a tremendous success, demonstrating first-hand the importance of precision diagnostics. The FDA granted accelerated approval of Bayer's VITRAKVI (larotrectinib) for adult and pediatric solid tumors containing NTRK fusions1. The approval was one of the first tissue agnostic approvals based on genotyping results, and included patients with unresectable or metastatic cancer. For 12 cancer types, the overall response rate was 75% with 22% complete response and 53% partial response. In addition to VITRAKVI, Genentech's entrectinib has a "breakthrough" status and is being evaluated for the potential treatment of advanced or metastatic tumors that harbor NTRK or ROS1 gene rearrangements. [Read More](https://blog.seracare.com/ngs/diagnostic-testing-schemes-for-ntrk-cancers-all-roads-lead-to-ngs) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/diagnostic-testing-schemes-for-ntrk-cancers-all-roads-lead-to-ngs#comments-listing) ## [Multi-Lab Study of Fusion RNA Reference Standards for Targeted NGS](https://blog.seracare.com/ngs/a-multi-lab-study-of-fusion-rna-reference-standards-using-targeted-ngs-panels) Category: [NTRK](https://blog.seracare.com/ngs/tag/ntrk), [NGS](https://blog.seracare.com/ngs/tag/ngs), [RNA fusion](https://blog.seracare.com/ngs/tag/rna-fusion), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials), [AACR](https://blog.seracare.com/ngs/tag/aacr) Posted by [Andrew Anfora, PhD](https://blog.seracare.com/ngs/author/andrew-anfora-phd) on Jan 28, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/NGS_MainFigure_CristinaSpan%C3%B2.jpg)](https://blog.seracare.com/ngs/a-multi-lab-study-of-fusion-rna-reference-standards-using-targeted-ngs-panels) Sourcing assay validation samples as positive run controls or workflow controls in targeted NGS RNA fusion assays remains a challenge today. This is further exacerbated with clinical labs looking to provide validated NGS assays for patient stratification in a host of new drugs in clinical trials or newly approved targeting fusion genes, such as NTRK genes (Larotrectinib, Loxo/Bayer) and Entrectinib (Genentech/Roche) for rare cancers in adult and pediatric patients, and RET (Loxo/Lilly) for lung cancer. SeraCare produces several RNA fusion reference materials. This article describes the development and multi-laboratory evaluation of a pan-cancer multiplexed Fusion RNA reference standard for analysis of clinically relevant fusion genes in solid tumors. The evaluation was conducted at 5 different laboratories on different NGS platforms (amplicon- and hybridization capture-based) as well as at different RNA inputs within a platform. Results highlight the utility of this Fusion RNA reference material to support clinical NGS assays as positive controls in solid tumor cancer patient stratification for many of these fusion-based targeted therapies. [Read More](https://blog.seracare.com/ngs/a-multi-lab-study-of-fusion-rna-reference-standards-using-targeted-ngs-panels) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/a-multi-lab-study-of-fusion-rna-reference-standards-using-targeted-ngs-panels#comments-listing) ## [Presenting NTRK Reference Materials for Global Assay Standardization at AACR 2019](https://blog.seracare.com/ngs/presenting-ntrk-reference-materials-for-global-assay-standardization-at-aacr-2019) Category: [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [NTRK](https://blog.seracare.com/ngs/tag/ntrk), [RNA fusion](https://blog.seracare.com/ngs/tag/rna-fusion), [AACR](https://blog.seracare.com/ngs/tag/aacr) Posted by [Catherine Huang, PhD](https://blog.seracare.com/ngs/author/catherine-huang-phd) on Apr 8, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/NTRK%20gene.jpg)](https://blog.seracare.com/ngs/presenting-ntrk-reference-materials-for-global-assay-standardization-at-aacr-2019) On the last morning of AACR 2019, I had the privilege of presenting a poster together with my colleague, Sebastian Bender from Bayer AG, in Berlin. Because of this, I didn’t have a chance to attend any talks, but I still wanted to finish out my blog series with highlights from each day of the conference. [Read More](https://blog.seracare.com/ngs/presenting-ntrk-reference-materials-for-global-assay-standardization-at-aacr-2019) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/presenting-ntrk-reference-materials-for-global-assay-standardization-at-aacr-2019#comments-listing) ## [NTRK Fusion Testing for New Therapies](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients) Category: [NTRK](https://blog.seracare.com/ngs/tag/ntrk), [cancer](https://blog.seracare.com/ngs/tag/cancer), [RNA fusion](https://blog.seracare.com/ngs/tag/rna-fusion) Posted by [Omo Clement, PhD](https://blog.seracare.com/ngs/author/omo-clement-phd) on Feb 6, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/NTRK_Cancer_Types.jpg)](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients) Neurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. TRK gene fusion-based cancers are rare but present in pediatric and adult cancers such as lung, thyroid, colon, etc. (see, e.g., Figure 1). [Read More](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients#comments-listing) [All posts](https://blog.seracare.com/ngs/all) ### Subscribe Here!   ### Posts by Tag - [NGS (64)](https://blog.seracare.com/ngs/tag/ngs) - [reference materials (37)](https://blog.seracare.com/ngs/tag/reference-materials) - [clinical genomics (30)](https://blog.seracare.com/ngs/tag/clinical-genomics) - [ctDNA (29)](https://blog.seracare.com/ngs/tag/ctdna) - [cancer (24)](https://blog.seracare.com/ngs/tag/cancer) - [SeraSeq (16)](https://blog.seracare.com/ngs/tag/seraseq) - [cfDNA (14)](https://blog.seracare.com/ngs/tag/cfdna) - [NIPT (12)](https://blog.seracare.com/ngs/tag/nipt) - [RNA fusion (11)](https://blog.seracare.com/ngs/tag/rna-fusion) - [AACR (10)](https://blog.seracare.com/ngs/tag/aacr) - [AMP (10)](https://blog.seracare.com/ngs/tag/amp) - [liquid biopsy (10)](https://blog.seracare.com/ngs/tag/liquid-biopsy) - [FDA (7)](https://blog.seracare.com/ngs/tag/fda) - [ccfDNA (7)](https://blog.seracare.com/ngs/tag/ccfdna) - [LDT (6)](https://blog.seracare.com/ngs/tag/ldt) - [Assay Development (5)](https://blog.seracare.com/ngs/tag/assay-development) - [Reproductive Health (5)](https://blog.seracare.com/ngs/tag/reproductive-health) - [Accuplex (4)](https://blog.seracare.com/ngs/tag/accuplex) - [NTRK (4)](https://blog.seracare.com/ngs/tag/ntrk) - [Non-invasive Prenatal Testing (4)](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing) - [QC Challenges (4)](https://blog.seracare.com/ngs/tag/qc-challenges) - [qc management (4)](https://blog.seracare.com/ngs/tag/qc-management) - [Lung Cancer (3)](https://blog.seracare.com/ngs/tag/lung-cancer) - [MRD (3)](https://blog.seracare.com/ngs/tag/mrd) - [New Reference Material (3)](https://blog.seracare.com/ngs/tag/new-reference-material) - [#Quality (2)](https://blog.seracare.com/ngs/tag/quality) - [EGFR (2)](https://blog.seracare.com/ngs/tag/egfr) - [Inherited Disease (2)](https://blog.seracare.com/ngs/tag/inherited-disease) - [Methylated DNA (2)](https://blog.seracare.com/ngs/tag/methylated-dna) - [Minimal Residual Disease (2)](https://blog.seracare.com/ngs/tag/minimal-residual-disease) - [Molecular Pathology (2)](https://blog.seracare.com/ngs/tag/molecular-pathology) - [PGT (2)](https://blog.seracare.com/ngs/tag/pgt) - [QC Management Software (2)](https://blog.seracare.com/ngs/tag/qc-management-software) - [TMB (2)](https://blog.seracare.com/ngs/tag/tmb) - [Women's health (2)](https://blog.seracare.com/ngs/tag/womens-health) - [myeloid cancer reference materials (2)](https://blog.seracare.com/ngs/tag/myeloid-cancer-reference-materials) - [ngs validation (2)](https://blog.seracare.com/ngs/tag/ngs-validation) - [trisomy (2)](https://blog.seracare.com/ngs/tag/trisomy) - [zika virus (2)](https://blog.seracare.com/ngs/tag/zika-virus) - [BioFidelity (1)](https://blog.seracare.com/ngs/tag/biofidelity) - [Breast Cancer (1)](https://blog.seracare.com/ngs/tag/breast-cancer) - [COVID-19 (1)](https://blog.seracare.com/ngs/tag/covid-19) - [Customer Testimonial (1)](https://blog.seracare.com/ngs/tag/customer-testimonial) - [Genomic Testing (1)](https://blog.seracare.com/ngs/tag/genomic-testing) - [HIV (1)](https://blog.seracare.com/ngs/tag/hiv) - [Immuno-Oncology (1)](https://blog.seracare.com/ngs/tag/immuno-oncology) - [PGS (1)](https://blog.seracare.com/ngs/tag/pgs) - [PGT-A (1)](https://blog.seracare.com/ngs/tag/pgt-a) - [Preimplantation genetic testing (1)](https://blog.seracare.com/ngs/tag/preimplantation-genetic-testing) - [QC Reporting (1)](https://blog.seracare.com/ngs/tag/qc-reporting) - [QC data management (1)](https://blog.seracare.com/ngs/tag/qc-data-management) - [Quality Management Systems (1)](https://blog.seracare.com/ngs/tag/quality-management-systems) - [SARS-CoV-2 (1)](https://blog.seracare.com/ngs/tag/sars-cov-2) - [bioinformatics (1)](https://blog.seracare.com/ngs/tag/bioinformatics) - [laboratory training (1)](https://blog.seracare.com/ngs/tag/laboratory-training) - [listeria (1)](https://blog.seracare.com/ngs/tag/listeria) - [methylated (1)](https://blog.seracare.com/ngs/tag/methylated) See all ### Recent Posts **About SeraCare** With over 30 years of experience as a leading partner to global in vitro diagnostics manufacturers and clinical testing laboratories, SeraCare’s clinical genomics technologies enable the promise of precision medicine by helping scientists and clinicians build and implement better clinical genomics assays. [Learn More](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx)    - - - [Privacy Policy](http://www.seracare.com/PrivacyPolicy/tabid/211/Default.aspx)  |  [Legal Statement ](http://www.seracare.com/LegalStatement/tabid/212/Default.aspx) **Learn More** [Home](http://seracare.com/)  [About Us](http://seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx)  [Blog](https://blog.seracare.com/)  [Contact](http://seracare.com/Contact/tabid/366/Default.aspx)  ![LGC+Marine-logo-FINAL-teal](https://blog.seracare.com/hs-fs/hubfs/1.%20Logos/LGC+Marine-logo-FINAL-teal.png?width=150&name=LGC+Marine-logo-FINAL-teal.png) 37 Birch Street Milford, MA 01757 [508-244-6400](tel:508-244-6400) l [800-676-1881](tel:800-676-1881) [info@seracare.com](mailto:info@seracare.com) ©2017 SeraCare Life Sciences, Inc. - [About SeraCare](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) - [Learn More](http://seracare.com/) - 37 Birch Street Milford, MA 01757 - Google Maps - 508-244-6400 - 508-634-3334 Fax - - - ![logo](https://blog.seracare.com/hubfs/logo.png "logo") 37 Birch Street Milford, MA 01757 508-244-6400 508-634-3334 Fax #### Products #### SeraCare #### Support & Resources - NGS & Digital PCR Tools - Controls & Reference Materials - Validation & Qualification Materials - Plasma & Serum Diluents & Derivatives - Cell Culture Reagents - KPL Antibodies & Conjugates - KPL Immunoassay Reagents & Kits - About Us - Careers - Press Releases - News Articles - Quality Systems - Terms & Conditions - Privacy Policy & Legal Statement - Register for an Account - Contact Us - Sign In - Resource Library - FAQs - Scientific Posters - White Papers - Videos